- Home
- ALLR vs WINT Comparison
ALLR vs WINT Comparison
Compare ALLR & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- WINT
- Stock Information
- Founded
- ALLR 2004
- WINT 1992
- Country
- ALLR United States
- WINT United States
- Employees
- ALLR N/A
- WINT N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALLR Health Care
- WINT Health Care
- Exchange
- ALLR Nasdaq
- WINT Nasdaq
- Market Cap
- ALLR 4.0M
- WINT 3.6M
- IPO Year
- ALLR N/A
- WINT 1995
- Fundamental
- Price
- ALLR $0.85
- WINT $0.57
- Analyst Decision
- ALLR
- WINT Hold
- Analyst Count
- ALLR 0
- WINT 1
- Target Price
- ALLR N/A
- WINT $350.00
- AVG Volume (30 Days)
- ALLR 564.1K
- WINT 260.9K
- Earning Date
- ALLR 08-04-2025
- WINT 05-16-2025
- Dividend Yield
- ALLR N/A
- WINT N/A
- EPS Growth
- ALLR N/A
- WINT N/A
- EPS
- ALLR N/A
- WINT N/A
- Revenue
- ALLR N/A
- WINT N/A
- Revenue This Year
- ALLR N/A
- WINT N/A
- Revenue Next Year
- ALLR N/A
- WINT N/A
- P/E Ratio
- ALLR N/A
- WINT N/A
- Revenue Growth
- ALLR N/A
- WINT N/A
- 52 Week Low
- ALLR $0.61
- WINT $0.55
- 52 Week High
- ALLR $17.35
- WINT $737.44
- Technical
- Relative Strength Index (RSI)
- ALLR 39.03
- WINT 26.04
- Support Level
- ALLR $0.78
- WINT $0.67
- Resistance Level
- ALLR $0.93
- WINT $0.81
- Average True Range (ATR)
- ALLR 0.07
- WINT 0.06
- MACD
- ALLR -0.02
- WINT 0.01
- Stochastic Oscillator
- ALLR 18.72
- WINT 5.24
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.